Antiproliferative activity of novel derivative of thiopyran on breast and colon cancer lines and DNA binding

Dimethyl-5-acetyl-4-methyl-6-(4-methylphenylimino)-6H-thiopyran-2,3-dicarboxylate (4) has been synthesized and its antiproliferative activity is reported here. Compound 4 inhibited the growth of human colon cancer cell line HCT-15 with an IC(50) value of 3.5 μM and of breast cancer cell line MCF-7 with an IC(50) value of 1.5 μM in a dose/time-dependent manner using a sulforhodamine B assay. Moreover, suppression of clonogenic activity occurred after exposure to 4 at a concentration of 4 μM for HCT-15 and 1.7 μM for MCF-7. The results also showed tumor cell invasion through matrigel and cell adhesion. The effect of ligand complexation on DNA structure led to overall affinity constant of K(4-DNA)=9.8×10(4) M(-1).     

Synthesis of novel inhibitors of β-glucuronidase based on benzothiazole skeleton and study of their binding affinity by molecular docking

Benzothiazole derivatives 1-26 have been synthesized and their in vitro β-glucuronidase potential has been evaluated. Compounds 4 (IC(50)=8.9 ± 0.25 μM), 5 (IC(50)=36.1 ± 1.80 μM), 8 (IC(50)=8.9 ± 0.38 μM), 13 (IC(50)=19.4 ± 1.00 μM), 16 (IC(50)=4.23 ± 0.054 μM), and 18 (IC(50)=2.26 ± 0.06 μM) showed β-glucuronidase activity potent than the standard (d-saccharic acid 1,4-lactone, IC(50)=48.4 ± 1.25 μM). Compound 9 (IC(50)=94.0 ± 4.16 μM) is found to be the least active among the series. All active analogs were also evaluated for cytotoxicity and none of the compounds showed any cytotoxic effect. Furthermore, molecular docking studies were performed using the gold 3.0 program to investigate the binding mode of benzothiazole derivatives. This study identifies a novel class of β-glucuronidase inhibitors.     

Inhibition of enkephalin-degrading enzymes from rat brain and of thermolysin by amino acid hydroxamates

Benzyloxycarbonyl derivatives (Z) of amino acid hydroxamates have been found to inhibit the bacterial metalloendopeptidase thermolysin and enkephalin-degrading enzymes from rat brain. The hydroxamate derivatives of glycine, leucine, phenylalanine and D-phenylalanine inhibit thermolysin with K_I values in the range of 3–23 μM. They also inhibit the enkephalin-degrading endopeptidase (enkephalinase) and aminopeptidase with different efficiencies, depending on the structure of the amino acid employed. Thus, Z-Gly-NHOH inhibits the enkephalinase and aminopeptidase with IC₅₀ values of 1 μM and 300 μM, respectively, whereas Z-D-Phe-NHOH inhibits the corresponding enzymes with IC₅₀ values of 0.2 μM and 1.5 μM.     

The G protein-coupled oestrogen receptor 1 agonist G-1 disrupts endothelial cell microtubule structure in a receptor-independent manner

The G protein-coupled oestrogen receptor GPER1, also known as GPR30, has been implicated in oestrogen signalling, but the physiological importance of GPER1 is not fully understood. The GPER1 agonist G-1 has become an important tool to assess GPER1-mediated cellular effects. Here, we report that this substance, besides acting via GPER1, affects the microtubule network in endothelial cells. Treatment with G-1 (3 μM) for 24 h reduced DNA synthesis by about 60 % in mouse microvascular endothelial bEnd.3 cells. Treatment with 3 μM G-1 prevented outgrowth of primary endothelial cells from mouse aortic explants embedded in Matrigel. Treatment with G-1 (0.3-3 μM) for 24 h disrupted bEnd.3 cell and HUVEC microtubule structure in a concentration-dependent manner as assessed by laser-scanning confocal immunofluorescence microscopy. G-1-induced (3 μM) disruption of microtubule was observed also after acute (3 and 6 h) treatment and in the presence of the protein synthesis inhibitor cycloheximide. Disruption of microtubules by 3 μM G-1 was observed in aortic smooth muscle cells obtained from both GPER1 knockout and wild-type mice, suggesting that G-1 influences microtubules through a mechanism independent of GPER1. G-1 dose dependently (10-50 μM) stimulated microtubule assembly in vitro. On the other hand, microtubules appeared normal in the presence of 10-50 μM G-1 as determined by electron microscopy. We suggest that G-1-promoted endothelial cell anti-proliferation is due in part to alteration of microtubule organization through a mechanism independent of GPER1. This G-1-promoted mechanism may be used to block unwanted endothelial cell proliferation and angiogenesis such as that observed in, e.g. cancer.     

A rational approach for the design and synthesis of 1-acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles as a new class of potential non-purine xanthine oxidase inhibitors

Xanthine oxidase is a complex molybdoflavoprotein that catalyses the hydroxylation of xanthine to uric acid. Fifty three analogues of 1-acetyl-3,5-diaryl-4,5-dihydro(1H)pyrazoles were rationally designed and synthesized and evaluated for in vitro xanthine oxidase inhibitory activity for the first time. Some notions about structure activity relationships are presented. Six compounds 41, 42, 44, 46, 55 and 59 were found to be most active against XO with IC(50) ranging from 5.3 μM to 15.2 μM. The compound 59 emerged as the most potent XO inhibitor (IC(50)=5.3 μM). Some of the important interactions of 59 with the amino acid residues of active site of XO have been figured out by molecular modeling.     

Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2

Allosteric targeting of protein kinases via displacement of the structural αC helix with type III allosteric inhibitors is currently gaining a foothold in drug discovery. Recently, the first crystal structure of CDK2 with an open allosteric pocket adjacent to the αC helix has been described, prospecting new opportunities to design more selective inhibitors, but the structure has not yet been exploited for the structure-based design of type III allosteric inhibitors. In this work we report the results of a virtual screening campaign that resulted in the discovery of the first-in-class type III allosteric ligands of CDK2. Using a combination of docking and post-docking analyses made with our tool BEAR, 7 allosteric ligands (hit rate of 20%) with micromolar affinity for CDK2 were identified, some of them inhibiting the growth of breast cancer cell lines in the micromolar range. Competition experiments performed in the presence of the ATP-competitive inhibitor staurosporine confirmed that the 7 ligands are truly allosteric, in agreement with their design. Of these, compound 2 bound CDK2 with an EC₅₀ value of 3 μM and inhibited the proliferation of MDA-MB231 and ZR-75–1 breast cancer cells with IC₅₀ values of approximately 20 μM, while compound 4 had an EC₅₀ value of 71 μM and IC₅₀ values around 4 μM. Remarkably, the most potent compound 4 was able to selectively inhibit CDK2-mediated Retinoblastoma phosphorylation, confirming that its mechanism of action is fully compatible with a selective inhibition of CDK2 phosphorylation in cells. Finally, hit expansion through analog search of the most potent inhibitor 4 revealed an additional ligand 4g with similar in vitro potency on breast cancer cells.     

Mild and efficient synthesis of new tetraketones as lipoxygenase inhibitors and antioxidants

A mild and efficient route to tetraketones (2–22) has been developed by way of tetraethyl ammonium bromide (Et₄N⁺Br^? ) mediated condensation of dimedone (5,5-dimethylcyclohexane-1,3-dione, 1) with a variety of aldehydes. All these compounds showed significant lipoxygenase inhibitory activity and moderate to strong antioxidant potential. Compounds 19 (IC₅₀ = 7.8 μM), 22 (IC₅₀ = 12.5 μM), 3 (IC₅₀ = 16.3 μM), 11 (IC₅₀ = 17.5 μM) and 8 (IC₅₀ = 21.3 μM) showed significant inhibitory potential against lipoxygenase (baicalein, IC₅₀ = 22.4 μM). On the other hand compound 19 (IC₅₀ = 33.6 μM) also showed strong antioxidant activity compared to the standard (IC₅₀ = 44.7 μM). This study is likely to lead to the discovery of therapeutically efficient agents against very important disorders including inflammation, asthma, cancer and autoimmune diseases.     

Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents

A series of caudatin derivatives were synthesized, and their anti-hepatitis B virus (HBV) activity was evaluated in HepG 2.2.15 cells. Most of the 3-O-substituted caudatin derivatives showed effective anti-HBV activity. Among the tested compounds, six compounds (2e-2h, 2l, 2r) exhibited significantly inhibitory activity against HBV DNA replication with IC(50) values in the range of 2.82-7.48 μM. Interestingly, two compounds (2e, 2f) had potent activity inhibiting not only the secretion of HBsAg (IC(50)=18.68 μM, 21.71 μM), HBeAg (IC(50)=13.16 μM, 33.73 μM), but also HBV DNA replication (IC(50)=7.48 μM, 3.63 μM). The structure-activity relationships (SARs) of caudatin derivatives had been discussed, which were useful for caudatin derivatives to be explored and developed as novel anti-HBV agents.     

Responses of cucumber to deficient and toxic amounts of nickel in nutrient solution containing urea as nitrogen source

Nickel (Ni) is an irreplaceable component of urease which reduces urea toxicity, but excess of Ni has detrimental effects on plant growth. The responses of cucumber (Cucumis sativus L. cvs. Negin and Dominus) plants supplied with urea as sole N source to four Ni concentrations (0, 50, 100 and 200 μM) were investigated. Nickel at a 50 μM concentration stimulated growth and reduced urea accumulation and lipid peroxidation in the leaves. However, the application of 100 and 200 μM Ni reduced a shoot dry mass and increased a malondialdehyde (MDA) content. An activity of catalase (CAT) was not affected by 50 μM Ni, whereas it was significantly increased by 200 μM Ni. The application of Ni resulted in an enhancement of a guaiacol peroxidase (GPX) activity in the leaves. An ascorbate peroxidase (APX) activity was reduced by 200 μM Ni in cv. Negin and by 100 μM Ni in cv. Dominus.     

Synthesis and evaluation of cardiac glycoside mimics as potential anticancer drugs

The cardiac glycoside digitoxin, consisting of a steroid core linked to a labile trisaccharide, has been used for centuries for the treatment of congestive heart failure. The well known pharmacological effect is a result of the ability of cardiac glycosides to inhibit the Na(+), K(+)-ATPase. Within recent years cardiac glycosides have furthermore been suggested to possess valuable anticancer activity. To mimic the labile trisaccharide of digitoxin with a stabile carbohydrate surrogate, we have used sulfur linked ethylene glycol moieties of varying length (mono-, di-, tri- or tetra-ethylene glycol), and furthermore used these linkers as handles for the synthesis of bivalent steroids. The prepared compounds were evaluated for their potencies to inhibit the Na(+), K(+)-ATPase and for their cytotoxic effect on cancerous MCF-7 cells. A clear trend is observed in both inhibition and cytotoxic effect, where the bioactivity decreases as the size increases. The most potent Na(+), K(+)-ATPase inhibitors are the compounds with the shortest ethylene glycol chain (K(app) 0.48 μM) and thiodigitoxigenin (K(app) 0.42 μM), which both are comparable with digitoxigenin (K(app) 0.52 μM). For the cancer cell viability assay the shortest mimics were found to have highest efficacy, with the best ligand having a monoethylene glycol unit (IC(50) 0.24 μM), which was slightly better than digitoxigenin (IC(50) 0.64 μM), while none of the novel cardiac glycoside mimics display an in vitro effect as high as digitoxin (IC(50) 0.02 μM).     

Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures

An increasing interest in the association of the presence of antibodies to Toxoplasma gondii and the development of schizophrenia in patients has been generated over the last several years. Some antischizophrenia agents have been shown to have activity against T. gondii in cell culture assays and to ameliorate behavioral changes associated with chronic T. gondii infection in rats. In the present study, we examined the effects of commonly used antipsychotic and mood stabilizing agents (haloperidol, clozapine, fluphenazine, trifluoperazine, and thioridazine) for activity against developing tachyzoites of the RH strain of T. gondii in human fibroblast cell cultures. Neither haloperidol nor clozapine had a measurable effect. Fluphenazine had an IC(50) of 1.7 μM, thioridazine had an IC(50) of 1.2 μM, and trifluoperazine had an IC(50) of 3.8 μM. Our study demonstrates that some agents used to treat schizophrenia have the ability to inhibit T. gondii proliferation in cell culture.     

Physiological and ultrastructural changes in <Emphasis Type="Italic">Arabidopsis thaliana</Emphasis> as affected by changed GSH level and Cu excess

We investigated the responses of wild-type Arabidopsis thaliana plants to the excess of Cu under conditions of the changed intracellular level of reduced glutathione (GSH) after application of buthionine sulfoximine (BSO) or exogenous GSH to the nutrient solution. BSO (500 μM) decreased and exogenous GSH (500 μM) increased GSH level, while increasing Cu concentration (from 5 to 50 μM) resulted in a decreased GSH content in the roots, but in its increased content in the shoots. BSO did not affect plant growth in contrast to exogenous GSH and Cu, which significantly reduced plant fresh weight. Both Cu and BSO or GSH induced changes in the root structure and leaf chloroplasts ultrastructure. Cu did not induce phytochelatin accumulation. Application of BSO or exogenous GSH did not significantly affect either the GSH level in the Cu-treated plants (except for 50/50 and 50/500 μM/μM Cu/GSH treatments increasing intracellular GSH content in the roots) or Cu toxicity to plants. These results suggest that GSH is not directly involved in Cu detoxification and tolerance in A. thaliana, yet it influences the proper anatomical structure of plants.     

AMPA receptor agonists: Resolution,configurational assignment,and pharmacology of (+)-(S)- and (-)-(R)-2-amino-3-[3-hydroxy-5-(2-pyridyl)-isoxazol-4-yl]-propionic acid (2-Py-AMPA)

We have previously shown that whereas (RS)-2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid (APPA) shows the characteristics of a partial agonist at (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors, (S)-APPA is a full AMPA receptor agonist and (R)-APPA a weak competitive AMPA receptor antagonist. This observation led us to introduce the new pharmacological concept, functional partial agonism. Recently we have shown that the 2-pyridyl analogue of APPA, (RS)-2-amino-3-[3-hydroxy-5-(2-pyridyl)isoxazol-4-yl]propionic acid (2-Py-AMPA), is a potent and apparently full AMPA receptor agonist, and this compound has now been resolved into (+)- and (-)-2-Py-AMPA (ee ≥ 99.0%) by chiral HPLC using a Chirobiotic T column. The absolute stereochemistry of the enantiomers of APPA has previously been established by X-ray analysis, and on the basis of comparative studies of the circular dichroism spectra of the enantiomers of APPA and 2-Py-AMPA, (+)- and (-)-2-Py-AMPA were assigned the (S)- and (R)-configuration, respectively. In a series of receptor binding studies, neither enantiomer of 2-Py-AMPA showed detectable affinity for kainic acid receptor sites or different sites at the N-methyl-D-aspartic acid (NMDA) receptor complex. (+)-(S)-2-Py-AMPA was an effective inhibitor of [³H]AMPA binding (IC⁵⁰ = 0.19 ± 0.06 μM) and a potent AMPA receptor agonist in the rat cortical wedge preparation (EC₅₀ = 4.5 ± 0.3 μM) comparable with AMPA (IC₅₀ = 0.040 ± 0.01 μM; EC₅₀ = 3.5 ± 0.2 μM), but much more potent than (+)-(S)-APPA (IC₅₀ = 5.5 ± 2.2 μM; EC₅₀ = 230 ± 12 μM). Like (-)-(R)-APPA (IC₅₀ > 100 μM), (-)-(R)-2-Py-AMPA (IC₅₀ > 100 μM) did not significantly affect [³H]AMPA binding, and both compounds were week AMPA receptor antagonists (K_i = 270 ± 50 and 290 ± 20 μM, respectively). Chirality 9:274–280, 1997. © 1997 Wiley-Liss, Inc.     

Inhibition of Human Immunodeficiency Virus Type-1 (HIV-1) Replication by Immunor (Im28), a New Analog of Dehydroepiandrosterone

Abstract

The inhibition of' HIV-I replication in vitro by Immunor 28 (IM²⁸), an analog of dehydroepiandrosterone (DHEA), was monitored using the HIV- 1 laboratory wild-type strain IIIB. Evaluation of the 50% inhibitory dose (IC₅₀) revealed a decrease in HIV-1 replication giving an IC, value around 22 μM. The toxicity of the drug has been determined also, in MT2 cells and PBMCs. 60 μM of IM²⁸ provoked a 50% decrease in cell viability while DHEA caused the same decrease at 75 μM in MT2 cells. These values are 125 μM for IM²⁸ in PBMCs and 135 μM for DIIBA. Thus, DHEA is less toxic than IM²⁸, but IM²⁸ has a higher antiviral activity.     

Taurine uptake by cultured human lymphoblastoid cells

Cultured human lymphoblastoid cells take up taurine from the medium by two processes: 1) a temperature-dependent, Na⁺-dependent, saturable “active”-transport system and 2) diffusion. The active transport has properties similar to those reported for taurine transport by other tissues. Apparent K_m is about 25 μM and V_max about 7.2 pmol/min/10⁶ cells; saturation occurs at 100 μM taurine. Uptake is competitively inhibited by the β-amino acids hypotaurine (50% inhibition at 44 μM) and β-alanine (50% at 152 μM), as measured at 50 μM taurine. Taurocyamine inhibits 50% at 260 μM. Chlorpromazine and imipramine are strong uncompetitive inhibitors, giving 50% inhibition at 26 μM and 115 μM, respectively; at these concentrations cellular viability per se is not affected. Ouabain inhibits 40–50% over a concentration range of 4–500 μM. Diffusion of taurine into the cells is proportional to concentration up to 20 mM. However, at the concentration of taurine in human plasma, 40–100 μM, active transport would provide 90% of the taurine taken up.     

6-Nitrobenzimidazole derivatives: potential phosphodiesterase inhibitors: synthesis and structure-activity relationship

6-Nitrobenzimidazole derivatives (1-30) synthesized and their phosphodiesterase inhibitory activities determined. Out of thirty tested compounds, ten showed a varying degrees of phosphodiesterase inhibition with IC(50) values between 1.5±0.043 and 294.0±16.7 μM. Compounds 30 (IC(50)=1.5±0.043 μM), 1 (IC(50)=2.4±0.049 μM), 11 (IC(50)=5.7±0.113 μM), 13 (IC(50)=6.4±0.148 μM), 14 (IC(50)=10.5±0.51 μM), 9 (IC(50)=11.49±0.08 μM), 3 (IC(50)=63.1±1.48 μM), 10 (IC(50)=120.0±4.47 μM), and 6 (IC(50)=153.2±5.6 μM) showed excellent phosphodiesterase inhibitory activity, much superior to the standard EDTA (IC(50)=274±0.007 μM), and thus are potential molecules for the development of a new class of phosphodiesterase inhibitors. A structure-activity relationship is evaluated. All compounds are characterized by spectroscopic parameters.     

Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv

In search of potential therapeutics for tuberculosis, we describe herein synthesis and biological evaluation of some substituted 4-arylthiazol-2-amino derivatives as modified analogues of the antiprotozoal drug Nitazoxanide (NTZ), which has recently been reported as potent inhibitor of Mtb H(37)Rv (Mtb MIC=52.12 μM) with an excellent ability to evade resistance. Among the synthesized derivatives, the two compounds 7a (MIC=15.28 μM) and 7c (MIC=17.03 μM) have exhibited about three times better Mtb growth inhibitory activity over NTZ and are free from any cytotoxicity (Vero CC(50) of 244 and 300 μM respectively). These two compounds represent promising leads for further optimization.     

Interaction of pyruvate kinase with isatin and deprenyl

The key glycolytic enzyme, pyruvate kinase, exhibits moderate affinity [³H]isatin binding (K_D ～10 μM) which is inhibited by ATP (IC₅₀ 25 μM) and deprenyl (IC₅₀ 5 μM). Interaction of pyruvate kinase with isatin and its inhibition by ATP and deprenyl has also been confirmed using an independent biosensor technique and the immobilized isatin analogue, aminoisatin. This effect has some specificity because the enzyme, creatine phosphokinase, does not exhibit specific isatin-binding. It is suggested that interaction of pyruvate kinase with isatin may reflect some non-glycolytic functions of this enzyme.     

Vinblastine inhibits the maturation of the precursor of mitochondrial aspartate aminotransferase. Vincristine and six other cytoskeleton inhibitors do not show this effect

Cytoskeleton inhibitors were tested in chicken embryo fibroblast cultures for possible effects on the import of the precursor of mitochondrial aspartate aminotransferase into mitochondria. Vinblastine (50 μM) increased the steady-state pool of the precursor 2.5-fold in pulse experiments with [³⁵S]methionine. If the precursor was accumulated during a pulse in the presence of the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) and then chased under diluting CCCP, vinblastine (50 μM) prolonged the half-life of the precursor from 0.5 min in the control to 3 min. Other cytoskeleton inhibitors, i.e. vincristine (25 to 150 μM), colchicine (50 μM), nocodazole (50 μM), podophyllotoxin (50 μM), taxol (45 μM), cytochalasin D (20 μM) and phalloidin (25 μM) did not show this effect. The observed inhibition by vinblastine does not seem to relate to its action on microtubuli.     

Synthesis and biological evaluation of novel N,N'-bis-methylenedioxybenzyl-alkylenediamines as bivalent anti-Alzheimer disease ligands

A novel series of N,N'-bis-methylenedioxybenzyl-alkylenediamines 5a-5g have been designed, synthesized and evaluated as bivalent anti-Alzheimer's disease ligands. The enzyme inhibition assay results indicated that compounds 5e-5g inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the micromolar range (IC(50), 2.76-4.24 μM for AChE and 3.02-5.14 μM for BuChE), which was in the same potential as the reference compound rivastigmine (IC(50), 5.50 μM for AChE and 1.60 μM for BuChE). It was found that compounds could bind simultaneously to the peripheral and catalytic sites of AChE. β-Amyloid (Aβ) aggregation inhibition assay results showed that compound 5e exhibited highest self-mediated Aβ fibril aggregation inhibition activity (40.3%) with a similar potential as curcumin (41.6%). It was also found that 5e-5g did not affect neuroblastoma cell viability at the concentration of 50 μM.